Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Garcia, Patrick L ^a   Council, Leona N ^b   Christein, John D ^c   Arnoletti, J Pablo ^d,e   Heslin, Marty J ^d   Gamblin, Tracy L ^a   Richardson, Joseph H ^d   Bjornsti, Mary Ann ^a   Yoon, Karina J ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GRAFT; CANCER STAGING; CANCER TRANSPLANTATION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MORPHOLOGY; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; TUMOR VOLUME; ANIMAL; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOPHYSIOLOGY; XENOGRAFT;

KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; HETEROGRAFTS; HUMANS; MICE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84886036947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078183     Document Type: Article

References (49)

1. Raimondi S, Maisonneuve P, Lowenfels AB, (2009) Epidemiology of pancreatic cancer: an overview. Nat. Rev Gastroenterol Hepatol 6: 699-708. doi:10.1038/nrgastro.2009.177.
2. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
3. Feldmann G, Maitra A, (2008) Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 10: 111-122. doi:10.2353/jmoldx.2008.070115. PubMed: 18258927.
4. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J, (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLOS Med 7: e1000267. PubMed: 20422030.
5. Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE, (2002) Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 160: 91-99. doi:10.1016/S0002-9440(10)64353-2. PubMed: 11786403.
6. Rubio-Viqueira B, Hidalgo M, (2009) Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 85: 217-221. doi:10.1038/clpt.2008.200. PubMed: 19005462.
7. De Wever O, Mareel M, (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447. doi:10.1002/path.1398. PubMed: 12845611.
8. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, et al. (2008) The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol/Hematol 65: 200-211. doi:10.1016/j.critrevonc.2007.10.003. PubMed: 18389522.
9. Kelland LR, (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40: 827-836. doi:10.1016/j.ejca.2003.11.028. PubMed: 15120038.
10. Hausser HJ, Brenner RE, (2005) Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 333: 216-222. doi:10.1016/j.bbrc.2005.05.097. PubMed: 15939397.
11. Maitra A, Hruban RH, (2008) Pancreatic cancer. Annu Rev Pathol 3: 157-188. doi:10.1146/annurev.pathmechdis.3.121806.154305. PubMed: 18039136.
12. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450. doi:10.1016/S1535-6108(03)00309-X. PubMed: 14706336.
13. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126. doi:10.1101/gad.1158703. PubMed: 14681207.
14. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. doi:10.1016/j.ccr.2005.04.023. PubMed: 15894267.
15. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, et al. (2006) Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146. doi:10.1101/gad.1478706. PubMed: 17114584.
16. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, et al. (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66: 95-106. doi:10.1158/0008-5472.CAN-05-2168. PubMed: 16397221.
17. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806. doi:10.1126/science.1164368. PubMed: 18772397.
18. Aggarwal BB, Danda D, Gupta S, Gehlot P, (2009) Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol 78: 1083-1094. doi:10.1016/j.bcp.2009.05.027. PubMed: 19481061.
19. Sausville EA, Burger AM, (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66: 3351-3354, discussion: 10.1158/0008-5472.CAN-05-3627. PubMed: 16585151.
20. Rygaard J, Povlsen CO, (1969) Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol Microbiol Scand 77: 758-760. PubMed: 5383844.
21. Giovanella BC, Yim SO, Morgan AC, Stehlin JS, Williams LJ Jr., (1973) Brief communication: metastases of human melanomas transplanted in "nude" mice. J Natl Cancer Inst 50: 1051-1053. PubMed: 4703769.
22. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, et al. (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49: 928-940. doi:10.1002/pbc.21078. PubMed: 17066459.
23. Fiebig HH, Maier A, Burger AM, (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40: 802-820. doi:10.1016/j.ejca.2004.01.009. PubMed: 15120036.
24. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652-4661. doi:10.1158/1078-0432.CCR-06-0113. PubMed: 16899615.
25. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, et al. (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17: 1514-1520. doi:10.1038/nm.2454. PubMed: 22019887.
26. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314. doi:10.1158/1535-7163.MCT-08-0924. PubMed: 19174553.
27. Baumgarten AJ, Fiebig HH, Burger AM, (2007) Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention. Cancer Genomics Proteomics 4: 223-231. PubMed: 17878525.
28. Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR, (2012) Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther 13: 935-945. doi:10.4161/cbt.20846. PubMed: 22785204.
29. Huynh H, Soo KC, Chow PK, Panasci L, Tran E, (2006) Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12: 4306-4314. doi:10.1158/1078-0432.CCR-05-2568. PubMed: 16857806.
30. Uronis JM, Osada T, McCall S, Yang XY, Mantyh C, et al. (2012) Histological and molecular evaluation of patient-derived colorectal cancer explants. PLOS ONE 7: e38422. doi:10.1371/journal.pone.0038422. PubMed: 22675560.
31. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7: 413-421. doi:10.1016/S1525-1578(10)60571-5. PubMed: 16049314.
32. Baines AT, Xu D, Der CJ, (2011) Inhibition of Ras for cancer treatment: the search continues. Future. J Med Chem 3: 1787-1808.
33. Wong HH, Lemoine NR, (2009) Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev Gastroenterol Hepatol 6: 412-422. doi:10.1038/nrgastro.2009.89.
34. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554. doi:10.1016/0092-8674(88)90571-5. PubMed: 2453289.
35. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, et al. (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16: 7773-7782. doi:10.1093/nar/16.16.7773. PubMed: 3047672.
36. Hruban RH, Maitra A, Kern SE, Goggins M, (2007) Precursors to pancreatic cancer. Gastroenterol Clin North Am 36: 831-849, vi doi:10.1016/j.gtc.2007.08.012. PubMed: 17996793.
37. Hong SM, Park JY, Hruban RH, Goggins M, (2011) Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 135: 716-727. PubMed: 21631264.
38. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, et al. (2012) Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 10: 125. doi:10.1186/1479-5876-10-125. PubMed: 22709571.
39. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, et al. (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3: 22. doi:10.1186/1479-5876-3-22. PubMed: 15943879.
40. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, et al. (2011) Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17: 5793-5800. doi:10.1158/1078-0432.CCR-11-0341. PubMed: 21742805.
41. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, et al. (2010) Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103: 649-655. doi:10.1038/sj.bjc.6605819. PubMed: 20664591.
42. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJ, et al. (1992) Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52: 5940-5947. PubMed: 1394220.
43. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, et al. (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17: 2799-2806. doi:10.1158/1078-0432.CCR-10-2580. PubMed: 21389100.
44. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, et al. (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10: 3-8. doi:10.1158/1535-7163.TARG-11-B3. PubMed: 21135251.
45. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, et al. (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10: 1311-1316. doi:10.1158/1535-7163.MCT-11-0233. PubMed: 21673092.
46. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, et al. (1995) Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55: 4670-4675. PubMed: 7553647.
47. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, et al. (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141: 2218-2227 e2215 doi:10.1053/j.gastro.2011.08.009. PubMed: 21864475.
48. Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, et al. (2012) Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 14: 519-525. PubMed: 22787433.
49. Fiebig HH, Schüler J, Bausch N, Hofmann M, Metz T, et al. (2007) Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 4: 197-209. PubMed: 17878523.